SMG1 , a nonsense‐mediated mRNA decay ( NMD ) regulator, as a candidate therapeutic target in multiple myeloma

Autor: Alexander C. Leeksma, Ingrid A. M. Derks, Brett Garrick, Aldo Jongejan, Martino Colombo, Timon Bloedjes, Torsten Trowe, Jim C. Leisten, Michelle Howarth, Mehnaz Malek, Deborah S. Mortensen, Kate Blease, Mathew C. Groza, Rama Krishna Narla, Remco Loos, Marie‐José Kersten, Perry D. Moerland, Jeroen E. J. Guikema, Arnon P. Kater, Eric Eldering, Ellen H. Filvaroff

Publikováno v: Molecular oncology. Elsevier
Leeksma, A C, Derks, I A M, Garrick, B, Jongejan, A, Colombo, M, Bloedjes, T, Trowe, T, Leisten, J C, Howarth, M, Malek, M, Mortensen, D S, Blease, K, Groza, M C, Narla, R K, Loos, R, Kersten, M-J, Moerland, P D, Guikema, J E J, Kater, A P, Eldering, E & Filvaroff, E H 2022, ' SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma ', Molecular oncology . https://doi.org/10.1002/1878-0261.13343

Early data suggested that CC-115, a clinical molecule, already known to inhibit the mammalian target of rapamycin kinase (TORK) and DNA-dependent protein kinase (DNA-PK) may have additional targets beyond TORK and DNA-PK. Therefore, we aimed to ident

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc34b2dab0571f6f622996e577edf883
https://doi.org/10.1002/1878-0261.13343

Data from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy

Autor: Atanasio Pandiella, Jesús San Miguel, Rajesh Chopra, Antonia Lopez-Girona, Deborah S. Mortensen, Bruno Paiva, Enrique M. Ocio, Elena Díaz-Rodríguez, Xi Chen

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates cell growth, proliferation, metabolism, and cell survival, and plays those roles by forming two functionally distinct multiprotein complexes: mTOR complex 1 (mTORC1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6326e356613d7ccd8f59b503b0a0e4a
https://doi.org/10.1158/1535-7163.c.6536587.v1

Supplementary Figure Legends from Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy

Autor: Atanasio Pandiella, Jesús San Miguel, Rajesh Chopra, Antonia Lopez-Girona, Deborah S. Mortensen, Bruno Paiva, Enrique M. Ocio, Elena Díaz-Rodríguez, Xi Chen

PDF file - 29K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ef3ac538e14f5dbe3b7035f51795947
https://doi.org/10.1158/1535-7163.22500838

Supplementary Figure 5 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Autor: Paul S. Mischel, Timothy F. Cloughesy, Rajesh Chopra, Kristen Hege, James R. Heath, Guido Kroemer, C. David James, Frank B. Furnari, Webster K. Cavenee, Heather K. Raymon, Shuichan Xu, Deborah S. Mortensen, Bruno Bonetti, Yuchao Gu, Alvaro Assuncao, Kelly Lin, David Akhavan, Ivan Babic, Kazuhiro Tanaka, Shaojun Zhu, David Shackelford, Genaro R. Villa, David Nathanson, Huijun Yang, Shiro Ikegami, Kenta Masui, Tomoo Matsutani, Deliang Guo, Ciro Zanca, Beatrice Gini

PDF file - 2080K, Tunable expression of EGFRvIII in genetically modified models correlates with autophagy induction upon CC214-1 treatment.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2b1de3c6f56240d0579ff3504b6433
https://doi.org/10.1158/1078-0432.22449398.v1

Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Autor: Paul S. Mischel, Timothy F. Cloughesy, Rajesh Chopra, Kristen Hege, James R. Heath, Guido Kroemer, C. David James, Frank B. Furnari, Webster K. Cavenee, Heather K. Raymon, Shuichan Xu, Deborah S. Mortensen, Bruno Bonetti, Yuchao Gu, Alvaro Assuncao, Kelly Lin, David Akhavan, Ivan Babic, Kazuhiro Tanaka, Shaojun Zhu, David Shackelford, Genaro R. Villa, David Nathanson, Huijun Yang, Shiro Ikegami, Kenta Masui, Tomoo Matsutani, Deliang Guo, Ciro Zanca, Beatrice Gini

PDF file - 5300K, CC214-1 synergizes at low doses with rapamycin. Quantification of the blots shown in Fig. 2B. PTEN detection on DEAL captured GBM39 cells upon CC214-1 treatment.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dcdf12758410788442ca9cf00c17376
https://doi.org/10.1158/1078-0432.22449410.v1